Immupharma (IMM)

 

Latest News

London Investor Evening

RNS Number: 9140E Immupharma PLC 15 February 2018 15 February 2018 ImmuPharma PLC ("ImmuPharma" or the "Company") London Investor Evening Monday 26 February 2018 @ 6pm ImmuPharma PLC (LSE: IMM) , specialist drug discovery and development company, is pleased to announce that Tim McCarthy, Chairman, will be presenting at an invest...

Holding(s) in Company

RNS Number: 4832E Immupharma PLC 09 February 2018 9 February 2018 ImmuPharma PLC ("ImmuPharma" or the "Company") Holding in Company ImmuPharma PLC (LSE: IMM) , the specialist drug discovery and development company, announces that on 8 February 2018 it received notification that Alto Invest no longer holds a notifiable interest in the Com...

Holding(s) in Company

RNS Number: 1713E Immupharma PLC 07 February 2018 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Immupharma p...

Holding(s) in Company

RNS Number: 8539D Immupharma PLC 05 February 2018 5 February 2018 ImmuPharma PLC ("ImmuPharma" or the "Company") Notification of Major Interest Lanstead Increases Holding to over 5% ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, has received notification that Lanstead Capital LP ("Lanstead") has confir...

All News

DateHeadlineSource
11-02-15Immupharma completes clinical trial StockMarketWire
11-02-15CANCER UPDATE: IPP-204106RNS
27-01-15ImmuPharma gets assurance over EIS StockMarketWire
27-01-15Enterprise Investment Scheme StatusRNS
22-01-15FTSE surges as ECB unveils QE, financials riseStockMarketWire
22-01-15FTSE cautiously up as ECB's QE call nearsStockMarketWire
22-01-15Collaboration Agreement with Simbec-OrionRNS
21-10-14FTSE 100 makes strong recoveryStockMarketWire
21-10-14FTSE 100 bounces backStockMarketWire
21-10-14ImmuPharma raises £3.4m StockMarketWire
20-10-14ImmuPharma unit awarded €400,000 grant StockMarketWire
30-09-14Losses remain at ImmuPharmaStockMarketWire
27-06-14Immupharma shareholders approve AGM resolutionsStockMarketWire
27-06-14ImmuPharma extends research capabilitiesStockMarketWire
16-06-14ImmuPharma granted new Nucant patents StockMarketWire
21-05-14ImmuPharma pre-tax losses riseStockMarketWire
06-05-14ImmuPharma gives summary from lupus conference StockMarketWire
23-04-14Lupuzor founder presents at Osaka UniversityStockMarketWire
27-09-13ImmuPharma trims operating lossStockMarketWire
13-08-13ImmuPharma gives update on cancer programmeStockMarketWire
08-07-13ImmuPharma appoints opinion leaders to advisory board StockMarketWire
08-07-13ImmuPharma appoints opinion leaders to advisory board StockMarketWire
21-05-13ImmuPharma agrees £50 financingStockMarketWire
09-04-13ImmuPharma losses riseStockMarketWire
28-02-13ImmuPharma starts trading on Stuttgart ExchangeStockMarketWire
28-01-13Director Deals - ImmuPharma PLC (IMM)StockMarketWire
28-01-13Director Deals - ImmuPharma PLC (IMM)StockMarketWire
28-01-13CNRS confirms Lupuzor's effectivenessStockMarketWire
26-09-12Markets: Global growth fears hit FTSE 100 on WednesdayInteractive Investor
26-09-12What's in store today...Interactive Investor
21-09-12The week ahead...Interactive Investor
02-04-12Hybridan's Small Cap WrapHybridan
27-03-12What's in store today...Interactive Investor
23-03-12The week ahead...Interactive Investor
14-11-11Hybridan's Small Cap WrapHybridan
30-10-11Hybridan's Small Cap WrapHybridan
21-10-11Markets: Eurozone hopes bolster FTSE 100 on FridayInteractive Investor
12-05-11Hybridan's Small Cap WrapHybridan
05-04-11Markets: FTSE 100 left with marginal lossesInteractive Investor
23-02-11Hybridan's Small Cap WrapHybridan

RSS feeds

  • Editorial news feed for LSE:IMM Editorial
  • Regulatory news feed for LSE:IMM Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account